Literature DB >> 16605281

Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.

Mohan V Bala1, Josephine A Mauskopf.   

Abstract

Assessing the cost effectiveness of a new health intervention often requires modelling to estimate the impact of the intervention on cost, survival and quality of life over the lifetime of a cohort of patients. Markov modelling is a methodology that is commonly employed to estimate these long-term costs and benefits. As commonly used, these models assume that the patients continue to get the treatments assigned regardless of the change in health states. In this paper, we describe an extension to the Markov modelling approach, called Markov decision modelling. Such a model starts with a set of health states and treatments and optimally assigns treatments to each of the health states. A Markov decision model can be used to identify the optimal treatment strategy not just for the initial disease state, but also as the disease state changes over time. We present a dynamic programming approach to identifying the optimal assignment of treatments, and illustrate this methodology using an example. The Markov decision modelling approach provides an efficient way of identifying optimal assignment of treatments to health states, but, like the standard Markov model, may be of limited use when probabilities of future events depend on past history in a complex fashion. Even with its limitations, Markov decision models offer an opportunity for health economists to inform healthcare decision-makers on how to modify current treatment pathways to incorporate new treatments as they become available.

Entities:  

Mesh:

Year:  2006        PMID: 16605281     DOI: 10.2165/00019053-200624040-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  16 in total

1.  A dynamic programming approach to the efficient design of clinical trials.

Authors:  K Claxton; K M Thompson
Journal:  J Health Econ       Date:  2001-09       Impact factor: 3.883

2.  Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?

Authors:  Mohan V Bala; Gary A Zarkin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  Taking account of future technology in cost effectiveness analysis.

Authors:  Joshua A Salomon; Milton C Weinstein; Sue J Goldie
Journal:  BMJ       Date:  2004-09-25

4.  Adjusting to changes in health: implications for cost-effectiveness analysis.

Authors:  Rajiv Sharma; Miron Stano; Mitchell Haas
Journal:  J Health Econ       Date:  2004-03       Impact factor: 3.883

5.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

6.  On pharmacogenomics and cost-effectiveness analysis at the individual level.

Authors:  Mohan V Bala; Gary A Zarkin
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?

Authors:  Adam La Caze
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  HIV antiretroviral treatment: early versus later.

Authors:  Josephine Mauskopf; Mari Kitahata; Teresa Kauf; Anke Richter; Jerry Tolson
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-15       Impact factor: 3.731

9.  Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

Authors:  J V Chancellor; A M Hill; C A Sabin; K N Simpson; M Youle
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

10.  Markov models in medical decision making: a practical guide.

Authors:  F A Sonnenberg; J R Beck
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

View more
  4 in total

1.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

2.  [Health Technology Assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz Tetra®].

Authors:  Sara Boccalini; Elena Pariani; Giovanna Elisa Calabrò; Chiara DE Waure; Donatella Panatto; Daniela Amicizia; Piero Luigi Lai; Caterina Rizzo; Emanuele Amodio; Francesco Vitale; Alessandra Casuccio; Maria Luisa DI Pietro; Cristina Galli; Laura Bubba; Laura Pellegrinelli; Leonardo Villani; Floriana D'Ambrosio; Marta Caminiti; Elisa Lorenzini; Paola Fioretti; Rosanna Tindara Micale; Davide Frumento; Elisa Cantova; Flavio Parente; Giacomo Trento; Sara Sottile; Andrea Pugliese; Massimiliano Alberto Biamonte; Duccio Giorgetti; Marco Menicacci; Antonio D'Anna; Claudia Ammoscato; Emanuele LA Gatta; Angela Bechini; Paolo Bonanni
Journal:  J Prev Med Hyg       Date:  2021-09-10

3.  Incentives for Optimal Multi-level Allocation of HIV Prevention Resources.

Authors:  Monali M Malvankar; Gregory S Zaric
Journal:  INFOR       Date:  2011-11-01       Impact factor: 1.588

4.  Effect of Integrative Chinese and Western Medicine Therapy on Long-Term Clinical Outcomes in Patients with Heart Failure: A Real-World Study Including 394 Patients.

Authors:  Zihan Wang; Jin Zhang; Gaoyu Zhang; Tianyi Lan; Ziyi Sun; Xiaoyan Lu; Li Huang; Lin Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-13       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.